Britain’s second-biggest drugmaker to improve Macclesfield facilities but is still not committing to manufacturing expansio.
AstraZeneca, Britain’s second-largest drugmaker, is to announce further investment in its Macclesfield site in northern England, in a boost for Britain’s £60bn life sciences industry.
The move, worth tens of millions of pounds, is expected to be announced this week when the government launches its industrial strategy for the sector in Birmingham on Wednesday.
However, there will not be an expansion of manufacturing. The investment will fund technical improvements at the packing site in Macclesfield, Cheshire. AstraZeneca’s £150m factory in Macclesfield produces breast cancer drugs such as Zoladex, one of the firm’s biggest-selling products. About 1,800 people work across the Macclesfield site.